THE CLIENT
AMR Action Fund We invest in companies that are developing urgently needed therapeutics for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Our aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation.
THE PROJECT
The team at AMR had set an ambitious but important goal to invest in and support the development of 2 to 4 novel antibiotics by 2030. To accelerate fundraising and the development cycle, the AMR leadership turned to Stark / Raving to create a sophisticated and science-first image that would solidify their messaging, increases brand recognition, and build trust among the antimicrobial research and investment community.